Direkt zum Inhalt
Merck
  • Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic chondrodysplasia-type Grebe.

Homozygous missense and nonsense mutations in BMPR1B cause acromesomelic chondrodysplasia-type Grebe.

European journal of human genetics : EJHG (2013-10-17)
Luitgard M Graul-Neumann, Alexandra Deichsel, Ulrike Wille, Naseebullah Kakar, Randi Koll, Christian Bassir, Jamil Ahmad, Valerie Cormier-Daire, Stefan Mundlos, Christian Kubisch, Guntram Borck, Eva Klopocki, Thomas D Mueller, Sandra C Doelken, Petra Seemann
ZUSAMMENFASSUNG

Acromesomelic chondrodysplasias (ACDs) are characterized by disproportionate shortening of the appendicular skeleton, predominantly affecting the middle (forearms and forelegs) and distal segments (hands and feet). Here, we present two consanguineous families with missense (c.157T>C, p.(C53R)) or nonsense (c.657G>A, p.(W219*)) mutations in BMPR1B. Homozygous affected individuals show clinical and radiographic findings consistent with ACD-type Grebe. Functional analysis of the missense mutation C53R revealed that the mutated receptor was partially located at the cell membrane. In contrast to the wild-type receptor, C53R mutation hindered the activation of the receptor by its ligand GDF5, as shown by reporter gene assay. Further, overexpression of the C53R mutation in an in vitro chondrogenesis assay showed no effect on cell differentiation, indicating a loss of function. The nonsense mutation (c.657G>A, p.(W219*)) introduces a premature stop codon, which is predicted to be subject to nonsense-mediated mRNA decay, causing reduced protein translation of the mutant allele. A loss-of-function effect of both mutations causing recessive ACD-type Grebe is further supported by the mild brachydactyly or even non-penetrance of these mutations observed in the heterozygous parents. In contrast, dominant-negative BMPR1B mutations described previously are associated with autosomal-dominant brachydactyly-type A2.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Guanidin -hydrochlorid, for molecular biology, ≥99%
Sigma-Aldrich
Guanidin -hydrochlorid, ≥98%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
L-Glutamin, meets USP testing specifications, suitable for cell culture, 99.0-101.0%, from non-animal source
Sigma-Aldrich
Guanidin -hydrochlorid, organic base and chaeotropic agent, ≥99% (titration)
Sigma-Aldrich
L-Glutamin, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Anti-HA in Kaninchen hergestellte Antikörper, affinity isolated antibody, buffered aqueous solution
SAFC
L-Glutamin
SAFC
Guanidin -hydrochlorid
Sigma-Aldrich
Guanidin -hydrochlorid -Lösung, Colorless liquid, 7.8 - 8.3 M, pH- 4.5 - 5.5
Sigma-Aldrich
L-Glutamin, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
L-(−)-Glukose, ≥99%
Sigma-Aldrich
Guanidin -hydrochlorid -Lösung, BioUltra, ~8 M in H2O
Sigma-Aldrich
Guanidin -hydrochlorid, ≥99.0% (AT)
Sigma-Aldrich
Guanidin -hydrochlorid, BioUltra, for molecular biology, ≥99.5% (AT)
Sigma-Aldrich
Guanidin -hydrochlorid, anhydrous, free-flowing, Redi-Dri, ≥99%
Sigma-Aldrich
L-Glutamin, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
L-Glutamin
Supelco
L-Glutamin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Glutamin, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland